Dose-related ocular adverse events ( chromatopsia , 57 % emixustat vs. 17 % placebo and delayed dark adaptation , 48 % emixustat vs. 6 % placebo ) were mild to moderate in severity , and the majority resolved on study or within 7 days to 14 days after study drug cessation .